Hiroaki Ozasa

MRP8/ABCC11 directly confers resistance to 5-fluorouracil

Tetsuya Oguri, Yuji Bessho, Hiroyuki Achiwa et al. · Molecular Cancer Therapeutics · 2007 · 131 citations

Medicine, Oncology, Pharmacology +15

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji et al. · Scientific Reports · 2017 · 119 citations · Full text

Medicine, Genetics, Oncology +17

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

Hiroaki Ozasa, Tetsuya Oguri, Takehiro Uemura et al. · Cancer Science · 2009 · 114 citations · Full text

Medicine, Oncology, Pharmacology +13

Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy

Ryusuke Hatae, Kenji Chamoto, Young Hak Kim et al. · JCI Insight · 2019 · 90 citations · Full text

Medicine, Immunology, Oncology +17

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Shoichi Hazama, Yusuke Nakamura, Hiroaki Tanaka et al. · Journal of Translational Medicine · 2014 · 87 citations · Full text

Medicine, Immunology, Pharmacology +17